These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38818295)

  • 1. Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis.
    Efremova I; Maslennikov R; Poluektova E; Medvedev O; Kudryavtseva A; Krasnov G; Fedorova M; Romanikhin F; Zharkova M; Zolnikova O; Bagieva G; Ivashkin V
    World J Hepatol; 2024 May; 16(5):822-831. PubMed ID: 38818295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.
    Efremova I; Maslennikov R; Poluektova E; Medvedev O; Kudryavtseva A; Krasnov G; Fedorova M; Romanikhin F; Bakhitov V; Aliev S; Sedova N; Kuropatkina T; Ivanova A; Zharkova M; Pervushova E; Ivashkin V
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiota and Biomarkers of Intestinal Barrier Damage in Cirrhosis.
    Efremova I; Maslennikov R; Medvedev O; Kudryavtseva A; Avdeeva A; Krasnov G; Romanikhin F; Diatroptov M; Fedorova M; Poluektova E; Levshina A; Ivashkin V
    Microorganisms; 2024 Feb; 12(3):. PubMed ID: 38543514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.
    Maslennikov R; Ivashkin V; Efremova I; Poluektova E; Kudryavtseva A; Krasnov G
    World J Gastroenterol; 2022 Mar; 28(10):1067-1077. PubMed ID: 35431497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis.
    Wu Z; Zhou H; Liu D; Deng F
    Front Cell Infect Microbiol; 2023; 13():1218552. PubMed ID: 37483387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.
    Villar-García J; Güerri-Fernández R; Moya A; González A; Hernández JJ; Lerma E; Guelar A; Sorli L; Horcajada JP; Artacho A; D Auria G; Knobel H
    PLoS One; 2017; 12(4):e0173802. PubMed ID: 28388647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Fukui H
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis.
    Papp M; Tornai T; Vitalis Z; Tornai I; Tornai D; Dinya T; Sumegi A; Antal-Szalmas P
    World J Gastroenterol; 2016 Nov; 22(41):9172-9185. PubMed ID: 27895404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids.
    Jin M; Kalainy S; Baskota N; Chiang D; Deehan EC; McDougall C; Tandon P; Martínez I; Cervera C; Walter J; Abraldes JG
    Liver Int; 2019 Aug; 39(8):1437-1447. PubMed ID: 30919578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.
    Riva A; Gray EH; Azarian S; Zamalloa A; McPhail MJW; Vincent RP; Williams R; Chokshi S; Patel VC; Edwards LA
    JHEP Rep; 2020 Dec; 2(6):100151. PubMed ID: 32838247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a Probiotic Containing
    Efremova I; Maslennikov R; Zharkova M; Poluektova E; Benuni N; Kotusov A; Demina T; Ivleva A; Adzhieva F; Krylova T; Ivashkin V
    J Clin Med; 2024 Feb; 13(3):. PubMed ID: 38337613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis.
    Maslennikov R; Ivashkin V; Efremova I; Alieva A; Kashuh E; Tsvetaeva E; Poluektova E; Shirokova E; Ivashkin K
    World J Hepatol; 2021 May; 13(5):557-570. PubMed ID: 34131470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS.
    Li M; Li K; Tang S; Lv Y; Wang Q; Wang Z; Luo B; Niu J; Zhu Y; Guo W; Bai W; Wang E; Xia D; Wang Z; Li X; Yuan J; Yin Z; Trebicka J; Han G
    JHEP Rep; 2022 May; 4(5):100448. PubMed ID: 35313729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial.
    Maslennikov R; Efremova I; Ivashkin V; Zharkova M; Poluektova E; Shirokova E; Ivashkin K
    World J Hepatol; 2022 Aug; 14(8):1667-1677. PubMed ID: 36157871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
    Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
    Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.
    Rainer F; Horvath A; Sandahl TD; Leber B; Schmerboeck B; Blesl A; Groselj-Strele A; Stauber RE; Fickert P; Stiegler P; Møller HJ; Grønbaek H; Stadlbauer V
    Aliment Pharmacol Ther; 2018 Mar; 47(5):657-664. PubMed ID: 29266346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Bowel Transit and Altered Gut Microbiota in Patients With Liver Cirrhosis.
    Liu Y; Jin Y; Li J; Zhao L; Li Z; Xu J; Zhao F; Feng J; Chen H; Fang C; Shilpakar R; Wei Y
    Front Physiol; 2018; 9():470. PubMed ID: 29780327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.